InspireMD, Inc. (NSPR) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:NSPRInspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.
(1.5)
InspireMD, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Revenue GrowthNSPR has had growing revenue for the last 2 years |
|
Price to Book (PBV) RatioUndervalued price-to-book. NSPR stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)NSPR equity is higher than it's debt. |
|
RevenueNSPR has positive revenue for last 5 years |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Net Income GrowthNSPR has never had growing net income. |
|
Net IncomeNSPR never has positive net income for 2 years. |
|
Dividend YieldNSPR has low dividend yield (0%). |
|
Return of AssetsNSPR has low return of asset (-63.23%). |
|
Return of EquityNSPR has low return of equity (-64.03%). |
|
Return of Invested CapitalNSPR has low ROIC. |
Competitors
InspireMD, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 4,495,000 USD
- Cost
- 19,211,000 USD
- Net Income
- -14,918,000 USD
- Profit Margin
- -331.88%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -13,554,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 565.97% |
Long Term Liabilities
| Liquidity/Current Ratio | 623.38% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -0.4x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 623.38% |
| Cash Ratio | 99.32% |
| Debt Ratio | 22.06% |
| Debt-Equity Ratio (DER) | 28.31% |
| Net Profit Margin (NPM) | -321.14% |
| Return of Assets (ROA) | -63.23% |
| Return of Equity (ROE) | -64.03% |
| Return on Capital Employed (ROCE) | -73.48% |
| Days of Sales Outstanding (DSO) | 90.7 |
| Days of Inventory Outstanding (DIO) | 119.69 |
| Days Payable Outstanding (DPO) | 34.2 |
| Operating Cycle (OC) | 142.06 |
| Cash Conversion Cycle (CCC) | 86.02 |
InspireMD, Inc. Executives
CEO
- CEO Name
- Dr. James Barry
Management
InspireMD, Inc. Profile
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Additional Information
- Company name
- InspireMD, Inc.
- Symbol
- NASDAQ:NSPR
- Exchange
- NASDAQ Capital Market
- Industry
- Medical Devices
- Sector
- Healthcare
- Address
-
4 Menorat Hamaor St.
TEL AVIV-YAFO
IL
6744832 - Website
- https://www.inspiremd.com